Mergers and acquisitions
CEOs Sean Duffy and Dan Rubinstein explain why their businesses just fit and what COVID-19 has to do with it.
This week's top stories include the ONC offering new funding for HIE innovation, a decline in healthcare M&A transactions and Medtronic's plans to buy a connected insulin pen startup.
After news broke about the $18.5 million deal all eyes in the digital health world have been on Livongo and Teladoc.
The company's smart insulin pen, dubbed the InPen, is slated to become part of Medtronics diabetes portfolio.
The MobiHealthNews team breaks down the week's big digital health news: Teladoc's proposed $18 billion acquisition of Livongo.
The deal is valued at roughly $4.7 billion.
Each Livongo share will be converted Teladoc stock at a 0.5920 exchange rate, plus an additional $11.44 in cash per stock.
The company will join the Nasdaq with an initial valuation around $720 million.
WhiteHatAI's technology can help address false claims, waste, abuse and fraud in the system.
Arkos Health will weave together Curavi Health, CarePointe and U.S. Health Systems' various care platforms for payer and provider customers.